Advertisement

Surgical Endoscopy

, Volume 24, Issue 3, pp 578–583 | Cite as

Activation of nuclear factor kappa B and induction of migration inhibitory factor in tumors by surgical stress of laparotomy versus carbon dioxide pneumoperitoneum: an animal experiment

  • Anwar Tawfik AminEmail author
  • Norio Shiraishi
  • Shigeo Ninomiya
  • Masaaki Tajima
  • Masafumi Inomata
  • Seigo Kitano
Article

Abstract

Background

Surgical trauma may be associated with enhanced tumor growth and establishment. The authors studied the effect of carbon dioxide (CO2) pneumoperitoneum versus laparotomy on tumor necrosis factor-α (TNFα), migration inhibitory factor (MIF) expression, and nuclear factor kappa B (NFκB) activity in human gastric cancer.

Methods

Nude mice were inoculated intraperitoneally with human gastric cancer cells (MKN45). Then laparotomy, CO2 pneumoperitoneum, and anesthesia alone were performed randomly. Tumor growth and associated TNFα and MIF expression and NFκB activity were determined.

Results

Total tumor weight, especially at the anterior abdominal wall, was higher after laparotomy than after CO2 pneumoperitoneum (p < 0.05). The mRNA expression of TNFα was higher 24 and 48 h after laparotomy than after CO2 pneumoperitoneum (p < 0.05 and p < 0.01, respectively). At all the examined time points, MIF mRNA expression also was higher after laparotomy than after CO2 pneumoperitoneum (p < 0.05 until 1 week or p < 0.01 at 2 weeks). The NFκB protein was more activated after laparotomy than after CO2 pneumoperitoneum 6 h subsequent to surgical procedures.

Conclusion

After CO2 pneumoperitoneum, tumors have less TNFα and MIF expression and less NFκB activity than after laparotomy. This may be associated with less tumor growth, supporting minimal invasive techniques in gastrointestinal oncologic surgery.

Keywords

Laparotomy MIF NFκPneumoperitoneum TNFα Tumor growth 

References

  1. 1.
    Allendorf JD, Bessler M, Horvath KD, Marvin MR, Laird DA, Whelan RL (1998) Increased tumor establishment and growth after open vs laparoscopic bowel resection in mice. Surg Endosc 12:1035–1038CrossRefPubMedGoogle Scholar
  2. 2.
    Bouvy ND, Marquet RL, Jeekel J, Bonjer HJ (1997) Laparoscopic surgery is associated with less tumor growth stimulation than conventional surgery: an experimental study. Br J Surg 84:358–361CrossRefPubMedGoogle Scholar
  3. 3.
    Abramovitch R, Marikovsky M, Meir G, Neeman M (1999) Stimulation of tumor growth by wound-derived growth factors. Br J Cancer 79:1392–1398CrossRefPubMedGoogle Scholar
  4. 4.
    Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RL (2006) Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg 244:792–798CrossRefPubMedGoogle Scholar
  5. 5.
    Lundberg O, Kristoffersson A (2005) Reduction of abdominal wall blood flow by clamping or carbon dioxide insufflation increases tumor growth in the abdominal wall: an experimental study in rats. Surg Endosc 19:720–723CrossRefPubMedGoogle Scholar
  6. 6.
    Kitano S, Iso Y, Moriyama M, Sugimachi K (1994) Laparoscopy-assisted Bilroth I gastrectomy. Surg Laparosc Endosc 2:146–148Google Scholar
  7. 7.
    Hiki N, Shimizu N, Yamaguchi H, Imamura K, Kubota K, Kaminishi M (2006) Manipulation of the small intestine as a cause of the increased inflammatory response after open compared with laparoscopic surgery. Br J Surg 93:195–204CrossRefPubMedGoogle Scholar
  8. 8.
    Ure BM, Neiwold TA, Bax NM, Ham M, van der Zee DC, Essen GJ (2002) Peritoneal, systemic, and distant organ inflammatory responses are reduced by a laparoscopic approach and carbon dioxide vs air. Surg Endosc 16:836–842CrossRefPubMedGoogle Scholar
  9. 9.
    Hayden M, Ghosh S (2004) Signaling to NF-kappa B. Genes Dev 18:2195–2224CrossRefPubMedGoogle Scholar
  10. 10.
    Wyke SM, Tisdale MJ (2005) NFκB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin–proteasome system in skeletal muscle. Br J Cancer 92:711–721CrossRefPubMedGoogle Scholar
  11. 11.
    Ravi R, Bedi A (2004) NFκB in cancer: a friend turned foe. Drug Resist Update 7:53–67CrossRefGoogle Scholar
  12. 12.
    Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R (1993) MIF is a pituitary derived cytokine that potentiates lethal endotoxeamia. Nature 365:756–759CrossRefPubMedGoogle Scholar
  13. 13.
    Calandra T, Bernhagen J, Mitchell R, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895–1902CrossRefPubMedGoogle Scholar
  14. 14.
    Bucala R (2000) A most interesting factor. Nature 408:167–168CrossRefGoogle Scholar
  15. 15.
    Mitchell R, Bucala R (2000) Tumor growth–promoting properties of MIF. Semin Cancer Biol 10:359–366CrossRefPubMedGoogle Scholar
  16. 16.
    Hira E, Ono T, Dhar D, El assal ON, Hishikawa Y, Yamanoi A, Nagasue N (2005) Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103:588–598CrossRefPubMedGoogle Scholar
  17. 17.
    Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005) Macrophages induce invasiveness of epithelial cancer cells via NFκB and JNK. J Immunol 175:1197–1205PubMedGoogle Scholar
  18. 18.
    Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S (2005) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti HER2 antobody in a murine model. Int J Oncol 27:681–685PubMedGoogle Scholar
  19. 19.
    Suematsu T, Shiromizu A, Yamaguchi K, Shiraishi N, Adachi Y, Kitano S (1999) Convenient murine pneumoperitoneal model for the study of laparoscopic cancer surgery. Surg Laparosc Endosc Per 9:279–281CrossRefGoogle Scholar
  20. 20.
    Haller D, Blum S, Bode C, Hammes WP, Schiffrin EJ (2000) Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: evidence of NK cells as primary targets. Infect Immun 68:752–759CrossRefPubMedGoogle Scholar
  21. 21.
    Kats R, Metz CN, Akoum A (2002) Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometrial lesions. J Clin Endocrinol Metab 87:883–889CrossRefPubMedGoogle Scholar
  22. 22.
    Narita T, Taga T, Sugita K, Nakazawa S, Ohta S (2001) The autocrine loop of epidermal growth factor receptor–epidermal growth factor/transforming factor alpha in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in TTC 549. Jpn J Cancer Res 92:269–278PubMedGoogle Scholar
  23. 23.
    Matsui Y, Inomata M, Izumi K, Sonoda K, Shiraishi N, Kitano S (2004) Hyaluronic acid stimulates tumor-cell proliferation at wound sites. Gastrointest Endosc 60:539–543CrossRefPubMedGoogle Scholar
  24. 24.
    Coffey JC, Wang JH, Bouchier-Hayes D, Cotter TG, Redmond HP (2006) The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. Ann Surg 243:250–256CrossRefPubMedGoogle Scholar
  25. 25.
    Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Menard S (2003) Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362:527–533CrossRefPubMedGoogle Scholar
  26. 26.
    Lee SW, Gleason N, Blanco I, Asi ZK, Whelan RL (2002) Higher colon cancer tumor proliferative index and lower tumor cell death rate in mice undergoing laparotomy vs insufflation. Surg Endosc 16:36–39CrossRefPubMedGoogle Scholar
  27. 27.
    Qadri S, Wang JH, Coffey JC, Alam M, O’Donnell A, Aherne T, Redmond HP (2004) Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg 79:990–995CrossRefGoogle Scholar
  28. 28.
    Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMedGoogle Scholar
  29. 29.
    Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 431:405–406CrossRefPubMedGoogle Scholar
  30. 30.
    Balkwill F (2002) Tumor necrosis factor or tumor-promoting factor? Cytokine Growth Factor Rev 13:134–135CrossRefGoogle Scholar
  31. 31.
    Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-pyest E, Urieli Shoval S, Galun E, Ben Neriah Y (2004) NFκB function as a tumor promoter in inflammation-associated cancer. Nature 431:461–466CrossRefPubMedGoogle Scholar
  32. 32.
    Jarnagin WR, Delman K, Kooby D, Mastorides S, Zager J, Brennan MF, Blumgart LH, Federoff H, Fong Y (2000) Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg 231:762–771CrossRefPubMedGoogle Scholar
  33. 33.
    Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Anwar Tawfik Amin
    • 1
    • 2
    Email author
  • Norio Shiraishi
    • 1
  • Shigeo Ninomiya
    • 1
  • Masaaki Tajima
    • 1
  • Masafumi Inomata
    • 1
  • Seigo Kitano
    • 1
  1. 1.Department of Gastroenterological SurgeryOita University Faculty of MedicineOitaJapan
  2. 2.South Egypt Cancer Institute, Surgery DepartmentAssiut UniversityAssiutEgypt

Personalised recommendations